Table of Contents
South Africa’s Saltzman family, founders of pharmacy chain Dis-Chem Pharmacies, has seen the market value of their joint stake in the healthcare soar above $630 million after several weeks of modest but steady gains on the Johannesburg Stock Exchange (JSE).
This reflects renewed investor interest in defensive retail stocks, even as pressure on household spending continues to weigh on parts of South Africa’s consumer sector. For the Saltzmans, the rise marks a solid recovery in the value of a business they built over more than four decades.
A long-standing family stake
The family owns 35.12 percent of Dis-Chem, equal to about 302 million shares. Over the past 34 trading days, the value of that stake has increased by R241.65 million ($14.51 million), lifting its total market value to roughly R10.54 billion ($633.11 million).
Dis-Chem was founded more than 40 years ago by Lynette and Ivan Saltzman in Gauteng. What began as a small pharmacy operation has grown into one of South Africa’s largest retail healthcare groups, with hundreds of stores nationwide.
Today, the company operates a broad network that includes dispensaries, family clinics, wound care centers, and self-medication outlets. Its footprint has made it a key player in a sector that tends to hold up better than many others during economic slowdowns.
Share gains lift market value
Dis-Chem shares have risen 2.35 percent over the past four weeks, climbing from R34.1 ($2.048) on Nov. 25 to R34.90 ($2.1), thus propelling the company’s market capitalization above $1.8 billion and adding to the wealth of long-term holders, including the founding family.
For the Saltzmans, the recent gains lifted their stake from R10.30 billion ($618.6 million) in late November to its current level above $630 million. While the increase is not dramatic, it underscores the steady nature of returns that pharmacy retailers can deliver in uncertain times.
Year-to-date picture remains mixed
Despite the recent lift, Dis-Chem shares remain down 3.32 percent for the year. A $100,000 investment in the company’s shares at the start of 2025 would now be worth $96,680, underscoring the uneven performance seen across the retail sector.
This highlights the balance investors are weighing: stable demand for healthcare products on one hand and tighter household budgets on the other. For the Saltzman family, the latest rise has pushed the value of their stake back above a key threshold, offering a reminder that even small share price moves can deliver major gains for major shareholders.
